Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Antibodies-Cytokeratin » Anti -Cytokeratin 19 Fragment (Cyfra 21-1 Antigen)

Anti -Cytokeratin 19 Fragment (Cyfra 21-1 Antigen)


  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.


Clone Host Grade Applications
Monoclonal Mouse Highly Purified E B
Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may correlate with response to therapy and survival in NSCLC. As part of CALGB 30203, a randomized trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton or both) in advanced NSCLC (Edelman JCO 2008), serum CYFRA levels were obtained prior to and during treatment. The objective of this study was to evaluate the possible correlation of CYFRA as a predictive and prognostic marker and to confirm a previous finding that a 27% reduction in CYFRA after one cycle (21 days) of treatment correlated with a longer survival (Vollmer Clin Ca Res, 2003).
Catalog #C9097-90
ApplicationsSuitable for use in ELISA and Western Blot. Other applications not tested.
Recommended DilutionOptimal dilutions to be determined by the researcher.
HybridomaSp2/0 myeloma cells with spleen cells from Balb/c mice.
Storage and StabilityMay be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Clone TypeMonoclonal
Clone No11H24
FormSupplied as a liquid in PBS, 0.05% sodium azide.
PurityPurified by Ion Exchange chromatography.
ImmunogenSoluble cytokeratin antigen fraction purified from human cell line
SpecificityRecognizes human Cyfra-21-1, Cytokeratin 19 fragment.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

External Links